8-K: Genprex Reqorsa Shows Positive Preclinical Data in Lung Cancer

Genprex announced positive preclinical data for its lead drug candidate, Reqorsa Gene Therapy, in ALK-EML4 positive non-small cell lung cancer.

Summary

• Genprex's research collaborators presented positive preclinical data for Reqorsa Gene Therapy (quaratusugene ozeplasmid) at the 2025 AACR-NCI-EROTC International Conference.
• The data relates to Reqorsa's efficacy in treating ALK-EML4 positive (ALK+) non-small cell lung cancer (NSCLC).
• Researchers demonstrated that Reqorsa can overexpress the tumor suppressor gene TUSC2 in EML4-ALK+ NSCLC cell lines and patient-derived organoids.
• Upregulation of TUSC2 by Reqorsa therapy induced apoptosis (programmed cell death) in ALK+ NSCLC cells, including those resistant to alectinib.
• Combining Reqorsa with alectinib further increased apoptosis in these cells.
• In *in vivo* mouse experiments using human ALK+-EML4 NSCLC cell line xenografts, combined treatment with Reqorsa and alectinib improved survival compared to control.
• These findings support the potential for a future clinical trial of Reqorsa in patients with ALK+-EML4 NSCLC.

Sentiment

Score: 8

Explanation: The filing reports strong positive preclinical data for a lead drug candidate in a significant cancer indication, opening a pathway for future clinical trials. This is a very positive development, though it remains at an early stage of drug development.

Positives

• Reqorsa Gene Therapy successfully overexpressed the tumor suppressor gene TUSC2 in ALK+ NSCLC cell lines and patient-derived organoids.
• Reqorsa therapy induced apoptosis in ALK+ NSCLC cells, including those demonstrating resistance to alectinib.
• The combination of Reqorsa with alectinib showed an even greater increase in apoptosis.
• In mouse xenograft models, the combination of Reqorsa and alectinib significantly improved survival.
• The positive preclinical data opens a pathway for a potential future clinical trial in ALK-positive lung cancer.

Risks

• Genprex's ability to advance the clinical development, manufacturing, and commercialization of its product candidates in accordance with projected timelines.
• The timing and success of Genprex's clinical trials and regulatory approvals, including beliefs about Reqorsa's potential as a therapeutic treatment.
• The effects of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes.
• The impact of any strategic research and development prioritization initiatives and the ability to implement them successfully.
• Genprex's future growth and financial status, including its ability to maintain compliance with Nasdaq Capital Market listing requirements and to continue as a going concern.
• The ability to obtain capital to meet long-term liquidity needs on acceptable terms, or at all.
• The performance of commercial and strategic partnerships, including third-party vendors, suppliers, and manufacturers.
• Risks related to Genprex's intellectual property and licenses.

Future Outlook

Genprex believes these positive preclinical data open a pathway for a potential future clinical trial in ALK-positive lung cancer. The company's ability to advance clinical development, achieve regulatory approvals, maintain financial stability, and secure necessary capital are subject to significant risks and uncertainties.

Management Comments

• The Company believes these positive data open a pathway for a potential future clinical trial in ALK-positive lung cancer.

Industry Context

The positive preclinical data for Reqorsa in ALK-EML4 positive NSCLC addresses a critical area within oncology, particularly for patients who may develop resistance to existing ALK inhibitors like alectinib. Combination therapies are increasingly recognized as a strategy to overcome resistance and improve outcomes in various cancers, positioning Reqorsa's potential as both a monotherapy and an adjunct therapy within a competitive landscape of targeted lung cancer treatments.

Stakeholder Impact

• Shareholders: Potential for increased company valuation and future growth prospects due to promising drug candidate data.
• Patients: Offers hope for a new therapeutic option, especially for those with ALK+ NSCLC resistant to current treatments.
• Medical Community: Provides new research insights and potential avenues for treating a challenging form of lung cancer.

Next Steps

• Potential future clinical trial in ALK-positive lung cancer.

Key Dates

Recommendation

The positive preclinical data for Reqorsa Gene Therapy in ALK-EML4 positive NSCLC, demonstrating apoptosis induction in resistant cells and improved survival in animal models, represents a significant de-risking event for the company's lead candidate. This opens a clear pathway for future clinical trials, which could unlock substantial value. While early-stage, the strong scientific rationale and promising results warrant a 'buy' recommendation for investors with a higher risk tolerance seeking exposure to potential breakthrough oncology therapies. However, investors should be mindful of the inherent risks associated with clinical development and the company's stated need for future capital.

Keywords

Genprex, Reqorsa, Gene Therapy, NSCLC, Lung Cancer, ALK-EML4, Preclinical Data, Oncology, TUSC2, Apoptosis, Alectinib, Cancer Therapeutics